Personalized Immunotherapy and Regulating Quality

摘要

Adoptive immunotherapy, chimeric antigen receptor (CAR) T cell therapy involves an infusion of the patient's own T cells that have been genetically engineered. Reprograming the T cells, and injecting the CART cells back into the patient encourages a positive immune response to fight the cancer cells and increase overall T cell survival as well as proliferation. Each CAR T cell therapy created is unique and specific to the patient, decreasing the potential riskfor adverse impacts to the patient's health. The patient's extracted T cells are manually modified outside of their body to create healthy CAR T cells which are then formulated into a therapeutic dose for infusion back into the patient. The manufacturers of each CART product are responsible for producing a safe and appropriate dose for each patient.The re-infusion is a one-time infusion with high risk and a long recovery of 2-3 months.